Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 756 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... August 6, 2025 “Your Stories” Podcast: Amplifying Patient Voices September 8, 2020 A Daily Survival Kit for Serious Illness September 8, 2021 Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs August 12, 2022 Load more HOT NEWS Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with... NCI Part of Federal Effort to Evaluate Antibody Tests for Novel... Foodie Fridays: Apple Bok Choy Salad How Are Eligibility Criteria for Clinical Trials Changing to Help People...
